Admixture Mapping of Peripheral Artery Disease in a Dominican Population Reveals a Novel Risk Locus on 2q35

Sinead Cullina; Genevieve L. Wojcik; Ruhollah Shemirani; Derek Klarin; Bryan R. Gorman; Elena P. Sorokin; Christopher R. Gignoux; Gillian M. Belbin; Saiju Pyarajan; Samira Asgari; Phil S. Tsao; Scott M. Damrauer; Noura S. Abul-Husn; Eimear E. Kenny

doi:10.1101/2023.03.27.23287788

Abstract

Peripheral artery disease (PAD) is a form of atherosclerotic cardiovascular disease, affecting ∼8 million Americans, and is known to have racial and ethnic disparities. PAD has been reported to have significantly higher prevalence in African Americans (AAs) compared to non-Hispanic European Americans (EAs). Hispanic/Latinos (HLs) have been reported to have lower or similar rates of PAD compared to EAs, despite having a paradoxically high burden of PAD risk factors, however recent work suggests prevalence may differ between sub-groups. Here we examined a large cohort of diverse adults in the BioMe biobank in New York City (NYC). We observed the prevalence of PAD at 1.7% in EAs vs 8.5% and 9.4% in AAs and HLs, respectively; and among HL sub-groups, at 11.4% and 11.5% in Puerto Rican and Dominican populations, respectively. Follow-up analysis that adjusted for common risk factors demonstrated that Dominicans had the highest increased risk for PAD relative to EAs (OR=3.15 (95% CI 2.33-4.25), P<6.44×10^-14). To investigate whether genetic factors may explain this increased risk, we performed admixture mapping by testing the association between local ancestry (LA) and PAD in Dominican BioMe participants (N=1,940) separately for European (EUR), African (AFR) and Native American (NAT) continental ancestry tracts. We identified a NAT ancestry tract at chromosome 2q35 that was significantly associated with PAD (OR=2.05 (95% CI 1.51-2.78), P<4.06×10^-6) with 22.5% vs 12.5% PAD prevalence in heterozygous NAT tract carriers versus non-carriers, respectively. Fine-mapping at this locus implicated tag SNP rs78529201 located within a long intergenic non-coding RNA (lincRNA) LINC00607, a gene expression regulator of key genes related to thrombosis and extracellular remodeling of endothelial cells, suggesting a putative link of the 2q35 locus to PAD etiology. In summary, we showed how leveraging health systems data helped understand nuances of PAD risk across HL sub-groups and admixture mapping approaches elucidated a novel risk locus in a Dominican population.

Competing Interest Statement

EEK received personal fees from Illumina, 23andMe, Allelica, and Regeneron Pharmaceuticals, received research funding from Allelica, and serves as a scientific advisory board member for Encompass Bio, Foresite Labs, and Galateo Bio. NSAH is an employee and equity holder of 23andMe; serves as a scientiﬁc advisory board member for Allelica; received personal fees from Genentech, Allelica, and 23andMe; received research funding from Akcea; and was previously employed by Regeneron Pharmaceuticals. EPS is an employee of Calico Life Sciences LLC. SA received consulting fees from Variant Bio and Biogen Inc. CRG owns stock in 23andMe and serves as an advisory board member for Encompass Bio. All other authors declare they have no disclosures to report. DK serve as scientific advisor to Bitterroot Bio, Inc. SMD receives research support from RenalytixAI and Novo Nordisk, outside the scope of the current research.

Funding Statement

EEK, NSAH, RS, SC were supported by U01 HG009080 from the National Institutes of Health (NIH) National Human Genome Research Institute (NHGRI) and National Institute for Minority Heath and Health Disparities of the National Institutes of Health. EEK, GMB, and CRG were supported by R01 HG011345 from NHGRI. CRG was also supported by R01 HG010297. The contents of this paper are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. SA was supported by the Sinsheimer Fund. DK is supported by the Department of Veterans Affairs Office of Research and Development, grant IK2BX005759-01. This research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration, and was supported by award BX003362 and the Million Veteran Program-MVP000. SMD is supported by the US Department of Veterans Affairs Clinical Research and Development award IK2-CX001780. This publication does not represent the views of the Department of Veteran Affairs or the United States Government.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Use of BioMe biobank in this study has been approved under an IRB approved study protocol and consent (IRB 07-0529)

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes